On 15 January 2015, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Lodipressin, intended for the treatment of systemic arterial hypertension in cats. The company that applied for authorisation is Le Vet Beheer B.V.
The applicant requested a re-examination of the opinion. After considering the grounds for this request, the CVMP re-examined the initial opinion, and confirmed the refusal of the marketing authorisation on 7 May 2015.
Questions and answers on the refusal of the marketing authorisation for Lodipressin (amlodipine besilate) (PDF/71.6 KB)Adopted
First published: 16/01/2015
Last updated: 29/04/2016
|International non-proprietary name (INN) or common name||
Le Vet Beheer B.V.
|Date of opinion||
|Date of refusal of marketing authorisation||